Skip to main content

Litfulo Disease Interactions

There are 3 disease interactions with Litfulo (ritlecitinib).

Major

JAK inhibitors (applies to Litfulo) cardiovascular risk

Major Potential Hazard, Moderate plausibility. Applicable conditions: Cardiovascular Disease, Smoking

In a major safety study of a Janus kinase (JAK) inhibitor, tofacitinib, in rheumatoid arthritis patients 50 years and older with at least 1 cardiovascular risk factor, higher rates of all-cause mortality (including sudden cardiovascular death) and major adverse cardiovascular events (MACE) (defined as cardiovascular death, myocardial infarction, and stroke) were observed with the JAK inhibitor when compared with tumor necrosis factor (TNF) blockers. Patients who were current or past smokers had an additional increased risk. Based on a shared mechanism of action, this risk should be considered for other JAK inhibitors, including baricitinib, upadacitinib, ruxolitinib, fedratinib, ritlecitinib, deuruxolitinib, and pacritinib. Consider the benefits and risks for each individual patient prior and during treatment with JAK inhibitors, especially in patients with other cardiovascular risk factors, history of cardiovascular events, and patients who are current or past smokers. Patients should be informed about the symptoms of serious cardiovascular events and what to do if they occur.

Switch to professional interaction data

Major

Ritlecitinib (applies to Litfulo) infections

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral, History - Tuberculosis, Immunodeficiency

Avoid the use of ritlecitinib in patients with an active, serious infection. Consider the risks and benefits of treatment in patients with chronic or recurrent infection, exposed to tuberculosis (TB), with a history of serious infection or an opportunistic infection, who have resided or traveled in areas of endemic TB or mycoses, or with underlying conditions that may predispose them to infection. Patients should be screened for TB before treatment initiation. This drug should not be given to patients with active TB or untreated latent TB; anti-TB therapy should be started prior to initiating treatment. Screening for viral hepatitis should be performed in accordance with clinical guidelines before starting therapy. Treatment interruption should be considered in patients with viral reactivation (e.g., herpes zoster).

Switch to professional interaction data

Moderate

Ritlecitinib (applies to Litfulo) hepatic dysfunction

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Ritlecitinib is not recommended in patients with severe (Child Pugh C) hepatic impairment.

Switch to professional interaction data

Litfulo drug interactions

There are 788 drug interactions with Litfulo (ritlecitinib).

Litfulo alcohol/food interactions

There is 1 alcohol/food interaction with Litfulo (ritlecitinib).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer